[Nearshore Protein: AI-enabled high-throughput wet experiments and data package services are still in the early stages of market expansion] On November 1st, Nearshore Protein (688137.SH) announced that the company’s stock’s closing price increase deviation for three consecutive trading days from October 28th to 30th accumulated more than 30%, which is an abnormal fluctuation in stock trading. The company's AI-enabled high-throughput wet experiments and data package services are still in the early stages of market expansion, and as of the third quarter of 2026, related business revenue accounts for less than 2% of the company's overall operating income. Given that the application of AI in the drug research and development industry is still in its infancy, there are risks such as rapid technology iteration, long industry verification cycles, and difficulty in commercialization. The company's future related income and profit realization are subject to significant uncertainty. Investors are reminded to view it rationally and pay attention to investment risks.